U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07564843) titled 'Theravex(R) for Burning Mouth Syndrome' on April 27.
Brief Summary: In this randomized, double-blind, placebo-controlled trial, 116 adults with primary BMS were assigned (1:1) to receive THERAVEX(R) Total Oral Care Plus or placebo for 8 weeks. Participants rinsed 10 mL for 60 seconds three times daily. The primary outcome was change in burning pain intensity (Numeric Rating Scale, NRS). Secondary outcomes included responder rate (>=2-point NRS reduction), Oral Health Impact Profile-14 (OHIP-14), Xerostomia Inventory, Patient Global Impression of Change (PGIC), and safety assessments.
Study Start Date: Oct. 06, 2024
Study Type: INTER...